logo-loader
viewCollagen Solutions PLC

Collagen Solutions inks significant manufacturing deal for wound-healing product

Jamal Rushdy, chief executive of Collagen Solutions PLC (LON:COS), discusses with Proactive Investors a manufacturing agreement that's been reached for the Excellagen product with Olaregen Therapeutix - a New York-based firm focused on products in the wound care market.

Collagen will manufacture Excellagen for Olaregen following a deal signed in September 2018 between the latter and US biotechnology firm Gene Biotherapeutics, for whom Collagen originally made the product and assisted in its development.

Excellagen is designed to treat wounds that are often complex and difficult to heal such as diabetic foot ulcers, burns, and venous (leg) or pressure ulcers among others.

Quick facts: Collagen Solutions PLC

Price: 3.4013 GBX

LSE:COS
Market: LSE
Market Cap: £15.09 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Collagen Solutions PLC named herein, including the promotion by the Company of Collagen Solutions PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Collagen Solutions released financial number showing more...

Collagen Solutions (LON: COS) CEO Jamal Rushdy joined Steve Darling from Proactive to discuss the company releasing their financial numbers that show impressive double-digit sales growth.  Rushdy talks about the numbers and also their tissue division that continues to be a revenue driver.

3 weeks, 6 days ago

2 min read